• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    HC Wainwright & Co. reiterated coverage on Ocugen with a new price target

    6/11/21 6:09:01 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OCGN alert in real time by email
    HC Wainwright & Co. reiterated coverage of Ocugen with a rating of Buy and set a new price target of $10.00 from $12.00 previously
    Get the next $OCGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OCGN

    DatePrice TargetRatingAnalyst
    10/15/2024$4.00Buy
    Maxim Group
    3/1/2023$3.50Neutral → Buy
    Chardan Capital Markets
    8/23/2022$5.00Buy
    Mizuho
    6/15/2022$8.00Buy
    ROTH Capital
    6/2/2022$4.50Overweight
    Cantor Fitzgerald
    2/28/2022$10.00 → $8.00Buy
    HC Wainwright & Co.
    7/26/2021Outperform
    Noble Capital Markets
    More analyst ratings